Author Question: A woman has been prescribed Climara, a transdermal estradiol patch. Which of the following should ... (Read 116 times)

deesands · **on:** Jul 23, 2018

A woman has been prescribed Climara, a transdermal estradiol patch. Which of the following should she be instructed by the nurse regarding the administration?

A) Avoid prolonged sun exposure at the patch site due to increased plasma concentrations.
B) The application of heat at the patch site will decrease effectiveness and result in pregnancy.
C) The medication, when exposed to sunlight, can increase the risk of breast cancer development.
D) Exposure of the medication to occasional cold will increase effectiveness with application once a month.

Question 2

A patient has been prescribed disopyramide (Norpace) to treat chronic ventricular tachycardia.

The nurse's subsequent cardiac assessments and monitoring should be planned in the knowledge that this drug has the potential to cause what health problem? A) New-onset chest pain
B) Mitral valve regurgitation
C) Acute renal failure
D) New dysrhythmias

ankilker · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

A
Feedback:
The total amount of drug absorbed and the resulting plasma drug concentrations from transdermal estrogen can increase during exposure to heat, so patients should be advised to avoid prolonged sun exposure in the area of the patch. The application of heat at the patch site will increase effectiveness. The medication's exposure to sunlight will not increase the risk of breast cancer. The medication's exposure to cold will not change its effectiveness.

Answer to Question 2

C
Feedback:
For disopyramide, the Food and Drug Administration (FDA) has issued a black box warning because of the drug's known prodysrhythmic properties. It is not specifically linked to chest pain, valvular regurgitation, or renal failure.